From Early Detection to Unravelling Mechanisms of Cardiotoxicity: The Role of Advanced Cardiovascular Imaging Modalities in Cardio-Oncology

Rox Burg^*
*Correspondence: Rox Burg, Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy, Email:

Introduction

Cardio-oncology is an emerging field that focuses on the cardiovascular complications associated with cancer treatment. While cancer therapies have advanced significantly in recent years, certain treatments, particularly chemotherapy and radiation, may inadvertently cause cardiotoxicity, leading to detrimental effects on the heart and overall cardiovascular health. As the number of cancer survivors continues to rise, understanding and mitigating these cardiotoxic effects have become paramount. Advanced cardiovascular imaging modalities play a crucial role in this endeavor, aiding early detection, monitoring treatment response, and uncovering the mechanisms behind cardiotoxicity. With remarkable progress in cancer treatments, there has been a substantial increase in cancer survivorship. However, the gains achieved in cancer management have come with a cost, as various chemotherapy agents and radiation therapies can cause damage to the heart. Cardiotoxicity encompasses a range of cardiovascular complications, including left ventricular dysfunction, heart failure, arrhythmias, and vascular disorders, which can significantly impact the quality of life and prognosis of cancer survivors. As a result, cardio-oncology has emerged as a multidisciplinary field that aims to address these cardiac issues and optimize cancer treatment while safeguarding the heart [1]. Advanced cardiovascular imaging techniques have revolutionized the field of cardiology, enabling non-invasive and precise evaluation of cardiac structure, function, and vascular status. Several imaging modalities are particularly relevant in the context of cardio-oncology. Echocardiography is a widely used and readily available imaging modality that uses ultrasound waves to create real-time images of the heart. It is an essential tool in assessing cardiac function, detecting structural abnormalities, and monitoring changes over time [2].

CMR provides detailed anatomical and functional information about the heart using magnetic fields and radiofrequency pulses. It offers highresolution images and is particularly valuable in assessing myocardial tissue characterization and fibrosis, which are critical in understanding cardiotoxicity. CT angiography allows for the assessment of coronary artery disease and vascular complications, making it useful in evaluating cancer patients at risk of cardiovascular events due to treatment-induced vascular damage. Techniques like Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) can assess myocardial perfusion and metabolism, aiding in the detection of early cardiac dysfunction and myocardial injury [3].

Early detection of cardiotoxicity is vital for preventing further damage and improving patient outcomes. Advanced cardiovascular imaging modalities play a key role in this regard, as they allow clinicians to identify subtle changes in cardiac function and structure even before symptoms become apparent. For instance, echocardiography can detect changes in Left Ventricular Ejection Fraction (LVEF), a critical indicator of cardiac function, enabling timely intervention if LVEF declines. Assessing the impact of cancer treatments on the heart is crucial in guiding therapeutic decisions and managing cardiotoxicity. Advanced cardiovascular imaging modalities, such as CMR, can track changes in cardiac function and myocardial tissue characteristics over time. This enables clinicians to adjust cancer therapies as needed to minimize the risk of further cardiotoxicity while maintaining optimal cancer treatment outcomes [4].

Description

Understanding the mechanisms behind cardiotoxicity is fundamental to developing effective prevention and treatment strategies. Advanced cardiovascular imaging modalities aid in this aspect by providing insights into the structural and functional changes occurring in the heart during cancer treatment. For example, CMR with T1 and T2 mapping sequences can detect early signs of myocardial inflammation and fibrosis, providing valuable information about the pathophysiological processes underlying cardiotoxicity.

Cardiovascular disease and cancer are two major health concerns that continue to affect millions of people worldwide. While advances in cancer therapies have led to improved survival rates, they have also brought to light an unfortunate side effect: cardiotoxicity. Cardio-oncology is an emerging field that focuses on the prevention, early detection, and management of cardiovascular complications in cancer patients. Advanced cardiovascular imaging modalities have emerged as powerful tools in the field of cardio-oncology, providing critical insights into early detection, assessment, and unraveling the mechanisms of cardiotoxicity associated with cancer treatments. This article explores the role of advanced cardiovascular imaging modalities in cardio-oncology, their applications, and their potential to improve patient outcomes.

Cardiovascular complications arising from cancer treatments, such as chemotherapy and radiation therapy, have become a significant concern for oncologists and cardiologists alike. Cardiotoxicity can manifest in various forms, including heart failure, arrhythmias, and myocardial damage. Identifying these complications at an early stage is crucial to implement timely interventions and prevent irreversible damage. Advanced cardiovascular imaging modalities, such as echocardiography, cardiac Magnetic Resonance Imaging (MRI), nuclear cardiology, and Computed Tomography (CT), have proven to be invaluable in the field of cardio-oncology. This article will discuss the key roles these modalities play in the early detection and understanding of cardiotoxicity in cancer patients. One of the primary objectives in cardio-oncology is the early detection of cardiotoxicity to allow for timely interventions. Echocardiography, a widely available and non-invasive imaging technique, has become the cornerstone in assessing cardiac function in cancer patients. Regular monitoring of Left Ventricular Ejection Fraction (LVEF) using echocardiography can identify subtle changes indicative of early cardiotoxicity. A decrease in LVEF may signal the onset of heart dysfunction, prompting clinicians to modify cancer treatments or introduce cardioprotective therapies [5].

Cardiac MRI provides a comprehensive assessment of cardiac structure, function, and tissue characterization. It has emerged as a powerful tool in cardio-oncology due to its high spatial resolution and ability to detect subtle cardiac abnormalities. Cardiac MRI can evaluate myocardial fibrosis, a hallmark of cardiotoxicity, and is particularly valuable in identifying cancer therapeutics associated with a higher risk of fibrosis, such as anthracyclines. The use of Late Gadolinium Enhancement (LGE) imaging can aid in the identification and quantification of myocardial fibrosis, enabling early intervention before symptomatic cardiotoxicity develops. Nuclear cardiology techniques, such as single-photon emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), play a vital role in cardio-oncology by providing insights into myocardial perfusion and viability. SPECT can identify perfusion defects, indicating areas of reduced blood flow, while PET can evaluate myocardial metabolism and viability. These techniques are particularly valuable in assessing the potential reversibility of myocardial damage caused by cancer treatments and in guiding decisions about the continuation or modification of therapy.

While CT is not as commonly used as other imaging modalities in cardiooncology, it does have specific applications, especially in assessing radiationinduced cardiotoxicity. Radiation therapy, a common cancer treatment, can lead to coronary artery disease, valvular abnormalities, and pericardial disease. CT angiography can provide detailed visualization of the coronary arteries, enabling early detection of radiation-induced coronary artery disease. Additionally, CT can aid in the assessment of pericardial thickening and calcifications, common manifestations of pericardial disease caused by radiation therapy.

Conclusion

Cardio-oncology has emerged as a critical field in addressing the cardiovascular complications arising from cancer treatments. Advanced cardiovascular imaging modalities, such as echocardiography, cardiac MRI, nuclear cardiology, and CT, play pivotal roles in the early detection, comprehensive assessment, and unravelling mechanisms of cardiotoxicity. By leveraging these imaging tools, oncologists and cardiologists can work together to implement timely interventions, minimize cardiac damage, and improve patient outcomes in the face of cancer and its treatments. Continued advancements in these imaging techniques hold the promise of further enhancing our understanding of cardio-oncology and optimizing patient care in this rapidly evolving field.

Beyond early detection, advanced cardiovascular imaging modalities offer valuable insights into the underlying mechanisms of cardiotoxicity associated with cancer treatments. For instance, speckle tracking echocardiography can assess myocardial strain, providing information about subtle changes in cardiac function before LVEF alterations become apparent. Cardiac MRI, with its tissue characterization capabilities, can identify specific patterns of fibrosis associated with different cancer therapies, shedding light on the pathophysiology of cardiotoxicity. These mechanistic insights may pave the way for the development of targeted cardioprotective strategies and personalized treatment plans for cancer patients at higher risk of cardiotoxicity.

Acknowledgement

None.

Conflict of Interest

There is no conflict of interest by author.

References

1. Chen, Jun-Zhang and Bo Liang. "Comparison of American and European guidelines for cardio-oncology of heart failure."Heart Fail Rev (2023): 1-10.

Google Scholar, Crossref, Indexed at

2. Upshaw, Jenica N., Brian Finkelman, Rebecca A. Hubbard and Amanda M. Smith, et al. "Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy."JACC Cardiovasc Imaging 13 (2020): 198-210.

Google Scholar, Crossref, Indexed at

3. Bernaba, Bob N., Jessica B. Chan, Chi K. Lai and Michael C. Fishbein. "Pathology of late-onset anthracycline cardiomyopathy."Cardiovasc Pathol 19 (2010): 308-311.

Google Scholar, Crossref, Indexed at

4. Neilan, Tomas G., Otavio R. Coelho-Filho, Diego Pena-Herrera and  Ravi V. Shah, et al. "Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines."Am J Cardiol 110 (2012): 1679-1686.

Google Scholar, Crossref, Indexed at

5. Drafts, Brandon C., Katie M. Twomley, Ralph D'Agostino and Julia Lawrence, et al. "Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease."JACC Cardiovasc Imaging 6 (2013): 877-885.

Google Scholar, Crossref, Indexed at